Company Overview and News
Stop missing out on important events!
Gilead/Kite, Iovance Biotherapeutics, bluebird bio, TiGenix, TissueGene, Adaptimmune and many more companies plus elite research institutions utilize its products. (140-2)
Pluristem (PSTI) is among the cell therapy companies which are racing to completion of a Phase III trial and initiation of two others in the coming months which look to address unmet needs in the medical community. Pluristem primarily utilizes two different placenta-derived cell products, (PDX-PAD and PLX-R18) which look to address a wide collection of therapeutic needs. Their lead product indications are Critical Limb Ischemia [CLI], Hip Fracture recovery and Acute Radiation Syndrome [ARS] (all Phase III) in addition to a Phase II trial in Intermittent Claudication [IC]. (135-3)
On October 31, I released a focus article on Bone Therapeutics (OTC:BNZPF). On one hand, I was fairly excited about the crucial phase III interim results on osteonecrosis that are expected in H2 2018. On the other hand, I also warned investors on the less comfortable cash position of the company. In my previous estimates, I presumed a cash runway until May 2018. This article is intended to discuss recent developments concerning the company's cash position.
Tigenix Sa (OTC:TGXSF) has 13 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 96,454,216 shares. Largest shareholders include Takeda Pharmaceutical Co Ltd, Grifols SA, Hillhouse Capital Management, Ltd., Alyeska Investment Group, L.P., Millennium Management Llc, EAM Investors, LLC, Diversified Trust Co, Deutsche Bank Ag\, Morgan Stanley, and UBS Group AG. (18-0)
TIG call was good timing, nothing more, but now investors may be looking for additional options. (52-1)
On the 5th of January, shareholders of TiGenix (NASDAQ:TIG) (OTC:TGXSF) were delighted with an unexpected treat. Japanese based medicine maker Takeda (OTCPK:TKPYY) (OTCPK:TKPHF) announced its intentions to acquire the Belgium-based biotech company. Takeda is offering €1.78 per share (~$2.14) - a premium of roughly 82% based on the last closing price of €0.98. This article intends to assess the bid.
Today we will discuss the hostile takeover bid from Novo Nordisk (NVO) for clinical-stage Belgian biotech company Ablynx (OTCPK:ABLYF). (411-6)
Today we will discuss Lipocine (LPCN), which fell more than 10% on Friday ahead of the Ad Com for its lead product candidate TLANDO, an oral testosterone replacement therapy (TRT). (243-7)
Today we will discuss an article on Synergy Pharmaceuticals (SGYP) by John Engle, titled, “Synergy’s New CEO: More Of The Same Or Change Of Course?” (496-2)
Today we will focus on Aclaris Therapeutics (ACRS). As we had expected, the FDA has approved its ESKATA topical solution, 40% for the treatment of raised seborrheic keratosis (non-cancerous skin growth). We had noted in our recent article that based on the data, an approval was likely. And as we expected, the stock has seen a pullback post approval. (142-3)
Tigenix (TIG) is a Belgian company that arrived on the US markets in December of 2016 following their IPO in Belgium the previous year. Their lead candidate, Cx601, now known in the EU market as Alofisel, is an adipose derived stem cell product designed to treat Crohn's disease related fistulas. They have recently seen success associated with their lead product and are expecting a CHMP marketing decision this month following convincing clinical trials.
A shot on three multibillion-dollar markets with highly unmet medical needs and very little competition (in two of the three markets). (24-3)
Even with an FDA approval, I have doubts about its sales, due to two existing approved drugs. (42-3)
July 13, 2017 - Grifols SA has filed a SC 13G form disclosing ownership of 41,929,954 shares of Tigenix Sa (OTC:TGXSF) corresponding to 16.1 percent ownership .
Leuven (BELGIUM) - June 29, 2017, 11:30h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions, today announces it has opened an U.S. office in Cambridge, Massachusetts. Establishing U.S. operations is a significant step for TiGenix and will support its strategic goal of developing and commercializing its lead product, Cx601, for the treatment of complex perianal fistulas in Crohn's disease patients, in the United States.